ArticleProceedings of the National Academy of Sciences of the United States of America1996
Epitope-specific tolerance induction with an engineered immunoglobulin.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 69 citations in OpenAlex.
- Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs.Frontiers in immunology · 2021Article
- Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.Haemophilia : the official journal of the World Federation of Hemophilia · 2020Review
- Tolerating Factor VIII: Recent Progress.Frontiers in immunology · 2019Review
- Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?Frontiers in immunology · 2019Review
- Review
- From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.Frontiers in immunology · 2017Review
- New therapies for hemophilia.Hematology. American Society of Hematology. Education Program · 2016Review
- Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.Critical reviews in biotechnology · 2015Review
- Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.Clinical and experimental medicine · 2014Review
- Antimicrobial peptides from scorpion venoms.Toxicon : official journal of the International Society on Toxinology · 2014Review
- Inhibitors - cellular aspects and novel approaches for tolerance.Haemophilia : the official journal of the World Federation of Hemophilia · 2014Review
- Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics.Expert review of clinical pharmacology · 2013Review
- Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se.Journal of leukocyte biology · 2013Article
- In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity.Journal of clinical immunology · 2013Review
- Tregitope peptides: the active pharmaceutical ingredient of IVIG?Clinical & developmental immunology · 2013Review
- B cells "transduced" with TAT-fusion proteins can induce tolerance and protect mice from diabetes and EAE.Clinical immunology (Orlando, Fla.) · 2011Article
- Potential application of tregitopes as immunomodulating agents in multiple sclerosis.Neurology research international · 2011Article
- Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Review
- Antigen-specific humoral tolerance or immune augmentation induced by intramuscular delivery of adeno-associated viruses encoding CTLA4-Ig-antigen fusion molecules.Gene therapy · 2009Article
- Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis.Seminars in arthritis and rheumatism · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Isologous and heterologous immunoglobulins have been shown to be extremely effective as tolerogenic carriers for nearly 30 years. The efficacy of these proteins is due in part to their long half-life in vivo, as well as their ability to crosslink surface IgM with Fc receptors. The concept of using IgG as a carrier molecule to induce unresponsiveness in the adult immune system has been exploited for simple haptens, such as nucleosides, as well as for peptides. To further evaluate the in vivo potential of these molecules for inducing tolerance to a defined epitope, we have engineered a fusion protein of mouse IgG1 with the immunodominant epitope 12-26 from bacteriophage lambda cI repressor protein. This 15-mer, which contains both a B-cell and T-cell epitope, has been fused in-frame to the N terminus of a mouse heavy chain IgG1 construct, thus creating a "genetic hapten-carrier" system. We describe a novel in vitro and in vivo experimental system for studying the feasibility of engineered tolerogens, consisting of a recombinant flagellin challenge antigen and a murine IgG1 tolerogen, both expressing the lambda repressor epitope 12-26. Herein, we show that peptide-grafted IgG molecules injected i.v., or expressed by transfected, autologous B cells, can efficiently modulate the cellular and humoral immune responses to immunodominant epitopes. This model displays the feasibility of "tailor-designing" immune responses to whole antigens by selecting epitopes for either tolerance or immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.